Palisade Bio's PALI-2108 Demonstrates Local Bioactivation And Dose Dependent Efficacy Response In Preclinical Mouse Models
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio's PALI-2108 shows promising preclinical results in mouse models for Ulcerative Colitis, demonstrating safety, efficacy, and local bioactivation. The company plans to start Phase 1 human trials by the end of the year.
May 21, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio's PALI-2108 has shown promising preclinical results in mouse models for Ulcerative Colitis, demonstrating safety, efficacy, and local bioactivation. The company is on track to start Phase 1 human trials by the end of the year.
The positive preclinical results and the upcoming Phase 1 human trials are likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100